首页> 外文期刊>Cell death & disease. >Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2
【24h】

Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2

机译:TNF相关凋亡诱导配体(TRAIL)死亡受体功能的分区化:核径r2的新兴作用

获取原文
           

摘要

Localized in the plasma membrane, death domain-containing TNF-related apoptosis-inducing ligand (TRAIL) receptors, TRAIL-R1 and TRAIL-R2, induce apoptosis and non-apoptotic signaling when crosslinked by the ligand TRAIL or by agonistic receptor-specific antibodies. Recently, an increasing body of evidence has accumulated that TRAIL receptors are additionally found in noncanonical intracellular locations in a wide range of cell types, preferentially cancer cells. Thus, besides their canonical locations in the plasma membrane and in intracellular membranes of the secretory pathway as well as endosomes and lysosomes, TRAIL receptors may also exist in autophagosomes, in nonmembraneous cytosolic compartment as well as in the nucleus. Such intracellular locations have been mainly regarded as hide-outs for these receptors representing a strategy for cancer cells to resist TRAIL-mediated apoptosis. Recently, a novel function of intracellular TRAIL-R2 has been revealed. When present in the nuclei of tumor cells, TRAIL-R2 inhibits the processing of the primary let-7 miRNA (pri-let-7) via interaction with accessory proteins of the Microprocessor complex. The nuclear TRAIL-R2-driven decrease in mature let-7 enhances the malignancy of cancer cells. This finding represents a new example of nuclear activity of typically plasma membrane-located cytokine and growth factor receptors. Furthermore, this extends the list of nucleic acid targets of the cell surface receptors by pri-miRNA in addition to DNA and mRNA. Here we review the diverse functions of TRAIL-R2 depending on its intracellular localization and we particularly discuss the nuclear TRAIL-R2 (nTRAIL-R2) function in the context of known nuclear activities of other normally plasma membrane-localized receptors.
机译:在血浆膜中局部化,死亡结构域与相关的细胞凋亡诱导配体(TRAIL)受体,TRAI-R1和TRAIL-R2,当由配体迹线或通过激动受体特异性抗体交联时诱导细胞凋亡和非凋亡信号传导。最近,增加的证据积累了痕迹受体在广泛的细胞类型中的非甘露吞噬细胞内位置,优先癌细胞。因此,除了血浆膜中的各种规范位置以及分泌途径的细胞内膜以及内体和溶酶体中,痕迹受体也可以存在于自噬体中,在非运动细胞溶质隔室以及细胞核中。这种细胞内位置主要被认为是这些受体的隐藏,代表抗癌细胞抵抗血迹介导的细胞凋亡的策略。最近,已经揭示了细胞内迹纵横-R2的新功能。当存在于肿瘤细胞的细胞核中,TRAIL-R2通过与微处理器络合物的辅助蛋白的相互作用抑制初级Let-7 miRNA(PRI-Let-7)的处理。成熟Let-7的核足迹-R2驱动降低增强了癌细胞的恶性肿瘤。该发现代表了典型的血浆膜定位细胞因子和生长因子受体的核活性的新示例。此外,除DNA和mRNA之外,这延伸了PRI-miRNA的细胞表面受体的核酸靶列表。在这里,我们根据其细胞内定位来审查TRAIL-R2的多样性功能,并且在其他通常血浆局部受体的已知核活性的背景下,我们特别讨论核润滑R2(Ntrail-R2)功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号